ImmunityBio, Inc. (IBRX)
Automate Your Wheel Strategy on IBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including IBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IBRX
- Rev/Share 0.0872
- Book/Share -0.602
- PB -10.5156
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 6234828450.0
- FreeCF/Share -0.3423
- PFCF -19.2424
- PE -17.1879
- Debt/Assets 0.0
- DivYield 0
- ROE 0.6278
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | IBRX | Piper Sandler | Neutral | Overweight | -- | $5 | May 20, 2025 |
| Initiation | IBRX | H.C. Wainwright | -- | Buy | -- | $8 | March 6, 2025 |
| Initiation | IBRX | BTIG Research | -- | Buy | -- | $6 | Jan. 10, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
Read More
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.
Read More
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Neutral
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphoma
Published: January 16, 2026 by: Proactive Investors
Sentiment: Positive
Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenström non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.
Read More
ImmunityBio: Why I Am Upgrading To A Buy For 2026
Published: January 15, 2026 by: Seeking Alpha
Sentiment: Positive
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but losses remain heavy and commercial traction is not yet spectacular. Anktiva shows superior duration of response versus competitors and promising survival data in NSCLC, supporting long-term revenue potential.
Read More
ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug
Published: January 15, 2026 by: Benzinga
Sentiment: Positive
ImmunityBio, Inc. (NASDAQ: IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.
Read More
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
Read More
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”
Published: December 29, 2025 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.” Soon-Shiong is the company's Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing the goal of a cancer-free society. On its website announcing the honor, OncoDaily highlighted.
Read More
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Read More
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy
Published: December 12, 2025 by: Benzinga
Sentiment: Positive
The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ.
Read More
ImmunityBio: A Small Bet Is Warranted
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Neutral
ImmunityBio should be rated as a speculative buy for aggressive investors only, offering significant upside despite ongoing dilution and cash burn concerns. Anktiva, IBRX's lead therapy, is ramping up sales post-J-code but faces competition from JNJ's TAR-200 and regulatory setbacks. Promising early data from the t-haNK program and expanding pipeline support the investment thesis for IBRX.
Read More
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Read More
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Recent ASCO data and UK MHRA approval for ANKTIVA reinforce my bullish thesis, despite the FDA's Refusal to File setback. ANKTIVA's potential to reverse lymphopenia in late-stage cancer patients could open significant new markets beyond bladder cancer. Major risks remain: FDA's RTF for sBLA and ImmunityBio's concerning cash position increase the likelihood of dilution.
Read More
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
Published: June 12, 2025 by: Seeking Alpha
Sentiment: Positive
ImmunityBio, Inc.'s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva's indications could reach $900 million by 2028, implying a 73% upside, but this is far from guaranteed. The company's lymphopenia treatment would face zero competition and would provide a larger addressable market.
Read More
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever.
Read More
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.
Read More
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
Published: May 05, 2025 by: Benzinga
Sentiment: Negative
ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.
Read More
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ImmunityBio to Host Investor Day
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. “ImmunityBio commenced 2025 with.
Read More
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago.
Read More
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on August 29, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company.
Read More
About ImmunityBio, Inc. (IBRX)
- IPO Date 2015-07-28
- Website https://immunitybio.com
- Industry Biotechnology
- CEO Richard Gerald Adcock
- Employees 671